naa a22 4500 510785956 CHVBK 20180411083302.0 cr unu---uuuuu 180411e20131101xx s 000 0 eng 10.1007/s12603-013-0368-1 doi (NATIONALLICENCE)springer-10.1007/s12603-013-0368-1 Association between illness progression measures and total cost in Alzheimer's disease [Elektronische Daten] [Loretto Lacey, T. Niecko, C. Leibman, E. Liu, M. Grundman] Objective: To compare the associations between dependence and clinical measures of cognition, function and behaviour and total care cost using data from a longitudinal study in Alzheimer's disease (AD). Design: Longitudinal, observational study. Setting: Community-dwelling subjects. Participants: Male and female subjects between 50 and 85 years of age with mild to moderate AD. Intervention: None. Measurements: Subject dependence was assessed using the Dependence Scale (DS), cognition (ADAS-Cog, MMSE), function (DAD), behaviour (NPI) and resource utilization with the Resource Utilization in Dementia Questionnaire. Results: The repeated measures models confirmed a significant association between the DS and total care cost indicating an increase in cost with increasing dependence. A 1-unit increase in DS score was associated with a 28.60% increase in total care cost. Model 2 indicated that a one point change in MMSE, DAD and NPI is associated with 5.29%, 2.32% and 1.71% increase in total cost, respectively. Model 3 indicated that a one point change in ADAS-Cog, DAD and NPI is associated with a 1.74%, 2.42%and 1.62% increase in total cost, respectively. Conclusion: Strategies which prevent deterioration in clinical measures or delay dependence should result in total cost savings. The quantitative relationships observed should assist in the economic assessment of interventions which effect cognition, function, behaviour and dependence. Serdi and Springer-Verlag France, 2013 Alzheimer's disease nationallicence dependence nationallicence cognition nationallicence function nationallicence behaviour nationallicence total care cost nationallicence longitudinal nationallicence Lacey Loretto Janssen Alzheimer Immunotherapy, Dublin, Ireland aut Niecko T. Niecko Health Economics, LLC, Naples Florida, USA aut Leibman C. Janssen Alzheimer Immunotherapy Research and Development, LLC, South San Francisco, California, USA aut Liu E. Janssen Alzheimer Immunotherapy Research and Development, LLC, South San Francisco, California, USA aut Grundman M. Global R&D Partners, LLC, San Diego, California, USA aut The journal of nutrition, health & aging Springer Paris 17/9(2013-11-01), 745-750 1279-7707 17:9<745 2013 17 12603 https://doi.org/10.1007/s12603-013-0368-1 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12603-013-0368-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lacey Loretto Janssen Alzheimer Immunotherapy, Dublin, Ireland aut NATIONALLICENCE 700 1- Niecko T. Niecko Health Economics, LLC, Naples Florida, USA aut NATIONALLICENCE 700 1- Leibman C. Janssen Alzheimer Immunotherapy Research and Development, LLC, South San Francisco, California, USA aut NATIONALLICENCE 700 1- Liu E. Janssen Alzheimer Immunotherapy Research and Development, LLC, South San Francisco, California, USA aut NATIONALLICENCE 700 1- Grundman M. Global R&D Partners, LLC, San Diego, California, USA aut NATIONALLICENCE 773 0- The journal of nutrition, health & aging Springer Paris 17/9(2013-11-01), 745-750 1279-7707 17:9<745 2013 17 12603 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer